Journal of Clinical Toxicology
Open Access
ISSN: 2161-0495
+44 1478 350008
ISSN: 2161-0495
+44 1478 350008
S. M. Marcus
Medical Director, New Jersey Poison Information & Education System, Professor, Department of Emergency Medicine, New Jersey Medical School, School of Biomedical and Health Science, Rutgers University 140 Bergen Street, Suite G1600, Newark, NJ 07101,
United States
Case Report
Iatrogenic Opioid-withdrawal Induced by Contrave®
Author(s): M. J. Zylstra, B. E. Ruck2 and S. M. Marcus
M. J. Zylstra, B. E. Ruck2 and S. M. Marcus
Introduction: New medications for the management of obesity are rapidly coming through the drug design pipeline. Among those recently approved is Contrave®, [naltrexone/bupropion] which has shown a modest and clinically relevant weight loss. We report two cases of naltrexone-induced opioid withdrawal resulting from the prescription of Contrave® to opioid-dependent patients. Case details: Patient 1 was a 59-year-old male with chronic pain prescribed morphine 60 mg and oxycodone 30 mg daily. He was prescribed Contrave® as adjunct to lifestyle modifications in the management of his obesity. Withdrawal symptoms precipitated within a few hours of his first dose. The resultant vomiting and anxiety led to patient distress and an emergency department visit. Patient 2 was a 42-year-old female former heroin user on methadone maintenance 90 mg daily. She was started on Contrave® .. View More»
DOI:
10.4172/2161-0495.1000289